)
)
AVROBIO Investor Relations Material
Latest events
M&A Announcement
AVROBIO
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from AVROBIO Inc
Access all reports
AVROBIO, Inc. is a clinical-stage biotechnology company specializing in the development of gene therapies using a lentiviral-based platform. These therapies are designed to treat rare diseases with a single dose, and involve modifying hematopoietic stem cells extracted from patients. AVROBIO focuses on a range of genetic disorders, employing its proprietary plato® platform to optimize these therapies. Notable diseases targeted by AVROBIO's gene therapies include Gaucher disease, Pompe disease, cystinosis, and Hunter syndrome, with several treatments in various stages of clinical trials. The company was established in 2015 and is based in Cambridge, Massachusetts. Its shares are listed on the NASDAQ.
Key slides for AVROBIO Inc
M&A Announcement
AVROBIO Inc
M&A Announcement
AVROBIO Inc
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
AVRO
Country
🇺🇸 United States